Transgenic 6F tomatoes act on the small intestine to prevent systemic inflammation and dyslipidemia caused by Western diet and intestinally derived lysophosphatidic acid

Journal of Lipid Research

Volumn 54, Issue 12, 2013, Pages 3403-3418

  Navab, Mohamad ^a   Hough, Greg ^a   Buga, Georgette M ^a   Su, Feng ^a   Wagner, Alan C ^a   Meriwether, David ^a   Chattopadhyay, Arnab ^a   Gao, Feng ^a   Grijalva, Victor ^a   Danciger, Janet S ^a   Van Lenten, Brian J ^a   Org, Elin ^a   Lusis, Aldons J ^a   Pan, Calvin ^a   Anantharamaiah, G M ^b   Farias Eisner, Robin ^a   Smyth, Susan S ^c   Reddy, Srinivasa T ^a   Fogelman, Alan M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b University of Alabama at Birmingham   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

Author keywords

6F peptide; Apolipoprotein A I mimetic peptides; Atherosclerosis; Genetically engineered tomato plants; Lysophosphatidic acid

Indexed keywords

6F PROTEIN; AMYLOID A PROTEIN; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDIC ACID; SATURATED LYSOPHOSPHATIDIC ACID; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UNSATURATED LYSOPHOSPHATIDIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIET; DYSLIPIDEMIA; FEMALE; GENE EXPRESSION; INFLAMMATION; LIQUID CHROMATOGRAPHY; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SMALL INTESTINE; TRANSGENIC PLANT; TRIACYLGLYCEROL BLOOD LEVEL; WESTERN DIET;

6F PEPTIDE; APOLIPOPROTEIN A-I MIMETIC PEPTIDES; ATHEROSCLEROSIS; GENETICALLY ENGINEERED TOMATO PLANTS; LYSOPHOSPHATIDIC ACID;

ANIMALS; APOLIPOPROTEIN A-I; DIET; DYSLIPIDEMIAS; FEMALE; GENE EXPRESSION REGULATION; INFLAMMATION; INTESTINE, SMALL; LYCOPERSICON ESCULENTUM; LYSOPHOSPHOLIPIDS; MICE; PEPTIDOMIMETICS; PLANTS, GENETICALLY MODIFIED; RECEPTORS, LDL; WESTERN WORLD;

EID: 84887920992     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M042051     Document Type: Article

References (42)

1. Getz, G. S., and C. A. Reardon. 2011. Apolipoprotein A-I and A-I mimetic peptides: a role in atherosclerosis. J. Inflamm. Res. 4:83-92.
2. Navab, M., S. T. Reddy, B. J. Van Lenten, G. M. Buga, G. Hough, A. C. Wagner, and A. M. Fogelman. 2012. High-density lipoprotein and 4F peptide reduce systemic inflammation by modulating intestinal oxidized lipid metabolism: novel hypotheses and review of literature. Arterioscler. Thromb. Vasc. Biol. 32:2553-2560.
3. Bloedon, L. T., R. Dunbar, D. Duffy, P. Pinell-Salles, R. Norris, B. J. DeGroot, R. Movva, M. Navab, A. M. Fogelman, and D. J. Rader. 2008. Safety, pharmacokinetics, and pharmacodynamics of oral apoA-I mimetic peptide D-4F in high-risk cardiovascular patients. J. Lipid Res. 49:1344-1352.
4. Watson, C. E., N. Weissbach, L. Kjems, S. Ayalasomayajula, Y. Zhang, I. Chang, M. Navab, S. Hama, G. Hough, S. T. Reddy, et al. 2011. Treatment of patients with cardiovascular disease with L-4F, an apo-A1 mimetic, did not improve select biomarkers of HDL function. J. Lipid Res. 52:361-373.
5. Navab, M., S. T. Reddy, G. M. Anantharamaiah, S. Imaizumi, G. Hough, S. Hama, and A. M. Fogelman. 2011. Intestine may be a major site of action for the apoA-I mimetic peptide 4F whether administered subcutaneously or orally. J. Lipid Res. 52:1200-1210.
6. Navab, M., S. T. Reddy, G. M. Anantharamaiah, G. Hough, G. M. Buga, J. Danciger, and A. M. Fogelman. 2012. D-4F-mediated reduction in metabolites of arachidonic and linoleic acids in the small intestine is associated with decreased inflammation in lowdensity lipoprotein receptor-null mice. J. Lipid Res. 53:437-445.
7. Chattopadhyay, A., M. Navab, G. Hough, F. Gao, D. Meriwether, V. Grijalva, J. R. Springstead, M. N. Palgnachari, R. Namiri-Kalantari, F. Su, et al. 2013. A novel approach to oral apoA-I mimetic therapy. J. Lipid Res. 54:995-1010.
8. Getz, G. S., and C. A. Reardon. 2013. ApoA-I mimetics: tomatoes to the rescue. J. Lipid Res. 54:878-880.
9. Aoki, J., A. Inoue, and S. Okudaira. 2008. Two pathways for lysophosphatidic acid production. Biochim. Biophys. Acta. 1781:513-518.
10. Mills, G. B., and W. H. Moolenaar. 2003. The emerging role of lysophosphatidic acid in cancer. Nat. Rev. Cancer. 3:582-591. (Pubitemid 37328830)
11. Schober, A., and W. Siess. 2012. Lysophosphatidic acid in atherosclerotic diseases. Br. J. Pharmacol. 167:465-482.
12. Shen, X., W. Wang, L. Wang, C. Houde, W. Wu, M. Tudor, J. R. Thompson, C. M. Sisk, B. Hubbard, and J. Li. 2012. Identification of genes affecting apolipoprotein B secretion following siRNA-mediated gene knockdown in primary human hepatocytes. Atherosclerosis. 222:154-157.
13. Dohi, T., K. Miyauchi, R. Ohkawa, K. Nakamura, M. Kurano, T. Kishimoto, N. Yanagisawa, M. Ogita, T. Miyazaki, A. Nishino, et al. 2013. Increased lysophosphatidic acid levels in culprit coronary arteries of patients with acute coronary syndrome. Atherosclerosis. 229:192-197.
14. Natarajan, V., W. M. Scribner, C. M. Hart, and S. Parthasarathy. 1995. Oxidized low density lipoprotein-mediated activation of phospholipase D in smooth muscle cells: a possible role in cell proliferation and atherogenesis. J. Lipid Res. 36:2005-2016.
15. Zhou, Z., P. Subramanian, G. Sevilmis, B. Globke, O. Soehnlein, E. Karshovska, R. Megens, K. Heyll, J. Chun, J. S. Saulnier-Blache, et al. 2011. Lipoprotein-derived lysophosphatidic acid promotes atherosclerosis by releasing CXCL1 from the endothelium. Cell Metab. 13:592-600.
16. Chen, C., L. N. Ochoa, A. Kagan, H. Chai, Z. Liang, P. H. Lin, and Q. Yao. 2012. Lysophosphatidic acid causes endothelial dysfunction in porcine coronary arteries and human coronary artery endothelial cells. Atherosclerosis. 222:74-83.
17. Llodrá, J., V. Angeli, J. Liu, E. Trogan, E. A. Fisher, and G. J. Randolph. 2004. Emigration of monocyte-derived cells from atherosclerotic lesions characterizes regressive, but not progressive, plaques. Proc. Natl. Acad. Sci. USA. 101:11779-11784. (Pubitemid 39095371)
18. Bot, M., I. Bot, R. Lopez-Vales, C. H. A. van de Lest, J. S. Saulnier-Blache, J. B. Helms, S. David, T. J. C. van Berkel, and E. A. L. Biessen. 2010. Atherosclerotic lesion progression changes lysophosphatidic acid homeostasis to favor its accumulation. Am. J. Pathol. 176:3073-3084.
19. Panchatcharam, M., S. Miriyala, A. Salous, J. Wheeler, A. Dong, P. Mueller, M. Sunkara, D. Escalante-Alcalde, A. J. Morris, and S. S. Smyth. 2013. Lipid phosphate phosphatase 3 negatively regulates smooth muscle cell phenotypic modulation to limit intimal hyperplasia. Arterioscler. Thromb. Vasc. Biol. 33:52-59.
20. Schunkert, H., I. R. König, S. Kathiresan, M. P. Reilly, T. L. Assimes, H. Holm, M. Preuss, A. F. Stewart, M. Barbalic, C. Gieger, et al. 2011. Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat. Genet. 43:333-338.
21. Bot, M., S. C. A. de Jager, L. MacAleese, H. M. Lagraauw, T. J. C. van Berkel, P. H. A. Quax, J. Kuiper, R. M. A. Heeren, E. A. L. Biessen, and I. Bot. 2013. Lysophosphatidic acid triggers mast celldriven atherosclerotic plaque destabilization by increasing vascular inflammation. J. Lipid Res. 54:1265-1274.
22. Dennis, G., Jr., B. T. Sherman, D. A. Hosack, J. Yang, W. Gao, H. C. Lane, and R. A. Lempicki. 2003. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 4:3.
23. Huang, D. W., B. T. Sherman, and R. A. Lempicki. 2009. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 4:44-57.
24. Yin, F., A. Lawal, J. Ricks, J. R. Fox, T. Larson, M. Navab, A. M. Fogelman, M. E. Rosenfeld, and J. A. Araujo. 2013. Diesel exhaust induces systemic lipid peroxidation and development of dysfunctional pro-oxidant and pro-inflammatory high-density lipoprotein. Arterioscler. Thromb. Vasc. Biol. 33:1153-1161.
25. Baker, D. L., D. M. Desiderio, D. D. Miller, B. Tolley, and G. J. Tigyi. 2001. Direct quantitative analysis of lysophosphatidic acid molecular species by stable isotope dilution electrospray ionization liquid chromatography-mass spectrometry. Anal. Biochem. 292:287-295.
26. de Wit, N. J. W., H. Bosch-Vermeulen, P. J. de Groot, G. J. E. J. Hooiveld, M. M. G. Bromhaar, J. Jansen, M. Müller, and R. van der Meer. 2008. The role of the small intestine in the development of dietary fat-induced obesity and insulin resistance in C57BL/6J mice. BMC Med. Genomics. 1:14.
27. Steegenga, W. T., N. J. W. de Wit, M. V. Boekschoten, N. Ijssennagger, C. Lute, S. Keshtkar, M. M. Bromhaar, E. Kampman, L. C. de Groot, and M. Muller. 2012. Structural, functional and molecular analysis of the effects of aging in the small intestine and colon of C57BL/6J mice. BMC Med. Genomics. 5:38.
28. Nakane, S., A. Tokumura, K. Waku, and T. Sugiura. 2001. Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: distinct molecular species compositions. Lipids. 36:413-419. (Pubitemid 32433878)
29. Tanaka, T., H. Tsutsui, K. Hirano, T. Koike, A. Tokumura, and K. Satouchi. 2004. Quantitative analysis of lysophosphatidic acid by time-of-flight mass spectrometry using a phosphate-capture molecule. J. Lipid Res. 45:2145-2150. (Pubitemid 40990911)
30. Tanaka, T., G. Horiuchi, M. Matsuoka, K. Hirano, A. Tokumura, T. Koike, and K. Satouchi. 2009. Formation of lysophosphatidic acid, a wound-healing lipid, during digestion of cabbage leaves. Biosci. Biotechnol. Biochem. 73:1293-1300.
31. Inoue, M., M. Adachi, Y. Shimizu, T. Tsutsumi, and A. Tokumura. 2011. Comparison of lysophospholipid levels in rat feces with those in a standard chow. J. Agric. Food Chem. 59:7062-7067.
32. Tanaka, T., A. Kassai, M. Ohmoto, K. Morito, Y. Kashiwada, Y. Takaishi, M. Urikura, J-I. Morishige, K. Satouchi, and A. Tokumura. 2012. Quantification of phosphatidic acid in foodstuffs using a thin-layer-chromatography-imaging technique. J. Agric. Food Chem. 60:4156-4161.
33. Zhu, P., Y. Y. Goh, H. F. A. Chin, S. Kersten, and N. S. Tan. 2012. Angiopoietin-like 4: a decade of research. Biosci. Rep. 32:211-219.
34. Robal, T., M. Larsson, M. Martin, G. Olivecrona, and A. Lookene. 2012. Fatty acids bind tightly to the N-terminal domain of angiopoietin-like protein 4 and modulate its interaction with lipoprotein lipase. J. Biol. Chem. 287:29739-29752.
35. Adachi, H., Y. Fujiwara, T. Kondo, T. Nishikawa, R. Ogawa, T. Matsumura, N. Ishii, R. Nagai, K. Miyata, M. Tabata, et al. 2009. Angptl 4 deficiency improves lipid metabolism, suppresses foam cell formation and protects against atherosclerosis. Biochem. Biophys. Res. Commun. 379:806-811.
36. Adachi, H., T. Kondo, G. Y. Koh, A. Nagy, Y. Oike, and E. Araki. 2011. Angptl4 deficiency decreases serum triglyceride levels in lowdensity lipoprotein receptor knockout mice and streptozotocin-induced diabetic mice. Biochem. Biophys. Res. Commun. 409:177-180.
37. Bäckhed, F., H. Ding, T. Wang, L. V. Hooper, G. Y. Koh, A. Nagy, C. F. Semenkovich, and J. I. Gordon. 2004. The gut microbiota as an environmental factor that regulates fat storage. Proc. Natl. Acad. Sci. USA. 101:15718-15723. (Pubitemid 39473554)
38. Fleissner, C. K., N. Huebel, M. M. Abd El-Bary, G. Loh, S. Klaus, and M. Blaut. 2010. Absence of intestinal microbiota does not protect mice from diet-induced obesity. Br. J. Nutr. 104:919-929.
39. Wang, Z., E. Klipfell, B. J. Bennett, R. Koeth, B. S. Levison, B. Dugar, A. E. Feldstein, E. B. Britt, X. Fu, Y. M. Chung, et al. 2011. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature. 472:57-63.
40. Bennett, B. J., T. Q. de Aguiar Vallim, Z. Wang, D. M. Shih, Y. Meng, J. Gregory, H. Allayee, R. Lee, M. Graham, R. Crooke, et al. 2013. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab. 17:49-60.
41. Koeth, R. A., Z. Wang, B. S. Levison, J. A. Buffa, E. Org, B. T. Sheehy, E. B. Britt, X. Fu, Y. Wu, L. Li, et al. 2013. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat. Med. 19:576-585.
42. Tang, W. H., Z. Wang, B. S. Levison, R. A. Koeth, E. B. Britt, X. Fu, Y. Wu, and S. L. Hazen. 2013. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N. Engl. J. Med. 368:1575-1584.